Evidence map›Paper›PMID 26937803›Full record

ArticleRadiology2016

CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.

Ying Liu, Jongphil Kim, Fangyuan Qu, Shichang Liu, Hua Wang, Yoganand Balagurunathan, Zhaoxiang Ye, Robert J Gillies

Abstract read
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. The application of radiomics in laryngeal cancer.The British journal of radiology · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Quantitative PCCT spectral parameters for noninvasive prediction of EGFR status and its subtypes in lung adenocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Imaging appearances, CT evolution patterns, and surgical prognosis of stage I lung squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying LiuFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Jongphil KimFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Fangyuan QuFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Shichang LiuFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Hua WangFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Yoganand BalagurunathanFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Zhaoxiang YeFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.
Robert J GilliesFrom the Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, PR China (Y.L., F.Q., S.L., H.W., Z.Y.); and Departments of Cancer Imaging and Metabolism (Y.L., H.W., Y.B., R.J.G.), Biostatistics and Bioinformatics (J.K.), and Radiology (R.J.G.), H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Radiomics of NSCLCU01CA143062 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GILLIES, ROBERT J., SCHABATH, MATTHEW B. · 2010 to 2020
$5.7M
NCI NIH HHS P30 CA076292NCI NIH HHS U01 CA143062
6 · The paper itself

Abstract

Purpose To retrospectively identify the relationship between epidermal growth factor receptor (EGFR) mutation status, predominant histologic subtype, and computed tomographic (CT) characteristics in surgically resected lung adenocarcinomas in a cohort of Asian patients. materials and Methods This study was approved by the institutional review board, with waiver of informed consent. Preoperative chest CT findings were retrospectively evaluated in 385 surgically resected lung adenocarcinomas. A total of 30 CT descriptors were assessed. EGFR mutations at exons 18-21 were determined by using the amplification refractory mutation system. Multiple logistic regression analyses were performed to identify independent factors of harboring EGFR mutation status. The final model was selected by using the backward elimination method, and two areas under the receiver operating characteristic curve (ROC) were compared with the nonparametric approach of DeLong, DeLong, and Clarke-Pearson. Results EGFR mutations were found in 168 (43.6%) of 385 patients. Mutations were found more frequently in (a) female patients (P < .001); (b)those who had never smoked (P < .001); (c)those with lepidic predominant adenocarcinomas (P = .001) or intermediate pathologic grade (P < .001); (e) smaller tumors (P < .001); (f)tumors with spiculation (P = .019), ground-glass opacity (GGO) or mixed GGO (P < .001), air bronchogram (P = .006), bubblelike lucency (P < .001), vascular convergence (P = .024), thickened adjacent bronchovascular bundles (P = .027), or pleural retraction (P < .001); and (g) tumors without pleural attachment (P = .004), a well-defined margin (P = .010), marked heterogeneous enhancement (P = .001), severe peripheral emphysema (P = .002), severe peripheral fibrosis (P = .013), or lymphadenopathy (P = .028). The most important and significantly independent prognostic factors of harboring EGFR-activating mutation for the model with both clinical variables and CT features were those who had never smoked and those with smaller tumors, bubblelike lucency, homogeneous enhancement, or pleural retraction when adjusting for histologic subtype, pathologic grade, or thickened adjacent bronchovascular bundles. ROC curve analysis showed that use of clinical variables combined with CT features (area under the ROC curve = 0.778) was superior to use of clinical variables alone (area under the ROC curve = 0.690). Conclusion CT imaging features of lung adenocarcinomas in combination with clinical variables can be used to prognosticate EGFR mutation status better than use of clinical variables alone. (©) RSNA, 2016 Online supplemental material is available for this article.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overErbB ReceptorsFemaleHumansLungLung NeoplasmsMaleMiddle AgedMutationRetrospective StudiesTomography, X-Ray ComputedErbB Receptors

Identifiers

PMID26937803
PMCPMC4934516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.